{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:05:47Z","timestamp":1770339947676,"version":"3.49.0"},"reference-count":112,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/grf.0000000000000072","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T15:37:33Z","timestamp":1413301053000},"page":"644-658","source":"Crossref","is-referenced-by-count":17,"title":["Progestins for Contraception"],"prefix":"10.1097","volume":"57","author":[{"given":"PAMELA A.","family":"ROYER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KIRTLY P.","family":"JONES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1977.tb29401.x","article-title":"The genesis of research on the progestins.","volume":"286","author":"Greep","year":"1977","journal-title":"Ann N Y Acad Sci"},{"key":"R2-4-20210126","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jsbmb.2006.09.023","article-title":". Progesterone and progestins: effects on brain, allopregnanolone and beta-endorphin.","volume":"102","author":"Pluchino","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R3-4-20210126","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1210\/en.2012-1138","article-title":". Progesterone receptors: a key for neuroprotection in experimental stroke.","volume":"153","author":"Liu","year":"2012","journal-title":"Endocrinology"},{"key":"R4-4-20210126","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.7770777","article-title":". Progesterone synthesis and myelin formation by Schwann cells.","volume":"268","author":"Koenig","year":"1995","journal-title":"Science"},{"key":"R5-4-20210126","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-118-5-199303010-00008","article-title":"Gastrointestinal motility disorders during pregnancy.","volume":"118","author":"Baron","year":"1993","journal-title":"Ann Intern Med"},{"key":"R6-4-20210126","first-page":"257","article-title":"Hormone therapies and venous thromboembolism: where are we now J Thromb Haemost.","volume":"9","author":"van Hylckama Vlieg","year":"2011","journal-title":""},{"key":"R8-4-20210126","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.contraception.2010.04.004","article-title":"The use of newer progestins for contraception.","volume":"82","author":"Sitruk-Ware","year":"2010","journal-title":"Contraception"},{"key":"R9-4-20210126","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use.","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"R10-4-20210126","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(97)00119-4","article-title":". First-time use of newer oral contraceptives and the risk of venous thromboembolism.","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"R11-4-20210126","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":". Hormonal contraception and risk of venous thromboembolism: national follow-up study.","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"R12-4-20210126","first-page":"811","article-title":"Commentary on Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.","volume":"120","author":"Cameron","year":"2013","journal-title":"BJOG"},{"key":"R13-4-20210126","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.contraception.2012.08.037","article-title":"Current status of contraceptive vaginal rings.","volume":"87","author":"Brache","year":"2013","journal-title":"Contraception"},{"key":"R14-4-20210126","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R15-4-20210126","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/01.AOG.0000175144.08035.74","article-title":"Extended regimens of the contraceptive vaginal ring: a randomized trial.","volume":"106","author":"Miller","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R16-4-20210126","first-page":"585","article-title":"Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.","volume":"100","author":"Dieben","year":"2002","journal-title":"Obstetrics and gynecology"},{"key":"R17-4-20210126","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.contraception.2010.05.016","article-title":"Progesterone vaginal ring for contraceptive use during lactation.","volume":"82","author":"Nath","year":"2010","journal-title":"Contraception"},{"key":"R18-4-20210126","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0010-7824(97)00008-5","article-title":". Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.","volume":"55","author":"Sivin","year":"1997","journal-title":"Contraception"},{"key":"R19-4-20210126","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0010-7824(98)00043-2","article-title":". The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.","volume":"57","author":"Chen","year":"1998","journal-title":"Contraception"},{"key":"R20-4-20210126","first-page":"223","article-title":". Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices.","volume":"56","author":"Diaz","year":"1997","journal-title":"Contraception"},{"key":"R21-4-20210126","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/09513590.2010.538095","article-title":". High levels of womens satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.","volume":"27","author":"Jakimiuk","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"R22-4-20210126","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":". Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"R23-4-20210126","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","article-title":"Contraceptive failure in the United States.","volume":"83","author":"Trussell","year":"2011","journal-title":"Contraception"},{"key":"R24-4-20210126","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-199855060-00019","article-title":"Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.","volume":"55","author":"Coukell","year":"1998","journal-title":"Drugs"},{"key":"R25-4-20210126","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":". Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"},{"key":"R26-4-20210126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0b013e318259565a","article-title":". Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.","volume":"120","author":"Xu","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R27-4-20210126","doi-asserted-by":"crossref","first-page":"388e1","DOI":"10.1016\/j.ajog.2012.08.002","article-title":". Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial.","volume":"207","author":"Mommers","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R28-4-20210126","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jcem-44-1-32","article-title":". Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.","volume":"44","author":"Ortiz","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-4-20210126","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.contraception.2014.01.026","article-title":". Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.","volume":"89","author":"Beasley","year":"2014","journal-title":"Contraception"},{"key":"R31-4-20210126","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.contraception.2011.09.015","article-title":"Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.","volume":"85","author":"Prabhakaran","year":"2012","journal-title":"Contraception"},{"key":"R32-4-20210126","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.contraception.2012.12.013","article-title":"New developments in contraception for US women.","volume":"87","author":"Dorflinger","year":"2013","journal-title":"Contraception"},{"key":"R33-4-20210126","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0010-7824(00)00183-9","article-title":"Lunelle Study G. Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 777 (norethindroneethinyl estradiol triphasic) or other oral contraceptives.","volume":"62","author":"Garceau","year":"2000","journal-title":"Contraception"},{"key":"R34-4-20210126","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0010-7824(90)90046-X","article-title":". Long-term contraception with the levonorgestrel 20 mcgday (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.","volume":"42","author":"Sivin","year":"1990","journal-title":"Contraception"},{"key":"R35-4-20210126","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.contraception.2012.09.034","article-title":". Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system.","volume":"87","author":"Natavio","year":"2013","journal-title":"Contraception"},{"key":"R36-4-20210126","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.contraception.2010.06.006","article-title":". Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability.","volume":"82","author":"Lewis","year":"2010","journal-title":"Contraception"},{"key":"R37-4-20210126","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0002-9378(99)70120-1","article-title":"The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices.","volume":"181","author":"Rivera","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R38-4-20210126","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/00006254-199612000-00014","article-title":"Mechanisms of action of intrauterine devices.","volume":"51","author":"Ortiz","year":"1996","journal-title":"Obstet Gynecol Surv"},{"key":"R39-4-20210126","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2307\/1966438","article-title":"IUDs are contraceptives, not abortifacients: a comment on research and belief.","volume":"20","author":"Sivin","year":"1989","journal-title":"Stud Fam Plan"},{"key":"R40-4-20210126","first-page":"1","article-title":"Report of a WHO Scientific Group.","volume":"753","year":"1987","journal-title":"World Health Organ Tech Rep Ser"},{"key":"R41-4-20210126","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/AOG.0b013e318227f05e","article-title":"ACOG Practice Bulletin No. 121: long-acting reversible contraception: implants and intrauterine devices.","volume":"118","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R42-4-20210126","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0039-128X(00)00119-7","article-title":". Nestorone: a progestin with a unique pharmacological profile.","volume":"65","author":"Kumar","year":"2000","journal-title":"Steroids"},{"key":"R44-4-20210126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jsbmb.2013.08.001","article-title":". Potency of progestogens used in hormonal therapy: toward understanding differential actions.","volume":"142","author":"Hapgood","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R45-4-20210126","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.steroids.2011.03.001","article-title":"Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.","volume":"76","author":"Africander","year":"2011","journal-title":"Steroids"},{"key":"R46-4-20210126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijgo.2009.08.020","article-title":". A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis.","volume":"108","author":"Kohler","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"R47-4-20210126","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/humrep\/dep469","article-title":". Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial.","volume":"25","author":"Strowitzki","year":"2010","journal-title":"Hum Reprod"},{"key":"R48-4-20210126","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2165\/11206320-000000000-00000","article-title":"Dienogest: a review of its use in the treatment of endometriosis.","volume":"70","author":"McCormack","year":"2010","journal-title":"Drugs"},{"key":"R49-4-20210126","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00003495-199856050-00007","article-title":"Dienogest.","volume":"56","author":"Foster","year":"1998","journal-title":"Drugs"},{"key":"R50-4-20210126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0010-7824(97)00123-6","article-title":". Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.","volume":"56","author":"Spona","year":"1997","journal-title":"Contraception"},{"key":"R51-4-20210126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejogrb.2009.11.001","article-title":". Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valeratedienogest): a phase III trial.","volume":"149","author":"Palacios","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R52-4-20210126","first-page":"1296","article-title":". Postcoital contraception with dienogest.","volume":"109","author":"Kohler","year":"1987","journal-title":"Zentralblatt fur Gynakologie"},{"key":"R53-4-20210126","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","article-title":". Conception and pharmacodynamic profile of drospirenone.","volume":"68","author":"Elger","year":"2003","journal-title":"Steroids"},{"key":"R54-4-20210126","first-page":"1816","article-title":". Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"R55-4-20210126","first-page":"633","article-title":". A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3 mg drospirenone0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.","volume":"12","author":"Palli","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"R56-4-20210126","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.contraception.2008.12.007","article-title":". Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada.","volume":"79","author":"Endrikat","year":"2009","journal-title":"Contraception"},{"key":"R57-4-20210126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.contraception.2013.12.003","article-title":"Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations.","volume":"89","author":"Stanczyk","year":"2014","journal-title":"Contraception"},{"key":"R58-4-20210126","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0010-7824(95)00270-7","article-title":"The effect of desogestrel, gestodene, and other factors on spotting and bleeding.","volume":"53","author":"Rosenberg","year":"1996","journal-title":"Contraception"},{"key":"R59-4-20210126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/09513599609041268","article-title":". A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene.","volume":"10","author":"Dusterberg","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"R60-4-20210126","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40268-013-0028-2","article-title":". Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.","volume":"13","author":"Junge","year":"2013","journal-title":"Drugs R D"},{"key":"R61-4-20210126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13625180400008940","article-title":". Combined ethinylestradiolgestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers.","volume":"9","author":"Heger-Mahn","year":"2004","journal-title":"Eur J Contracep Reprod Health Care"},{"key":"R62-4-20210126","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0010-7824(93)90117-P","article-title":". Pharmacokinetics and bioavailability of ST 1435 administered by different routes.","volume":"48","author":"Noe","year":"1993","journal-title":"Contraception"},{"key":"R63-4-20210126","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0010-7824(01)00199-8","article-title":". Ovarian function during use of vaginal rings delivering three different doses of Nestorone.","volume":"63","author":"Brache","year":"2001","journal-title":"Contraception"},{"key":"R64-4-20210126","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0039-128X(00)00125-2","article-title":". Vaginal rings for contraception in lactating women.","volume":"65","author":"Massai","year":"2000","journal-title":"Steroids"},{"key":"R65-4-20210126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.contraception.2004.08.010","article-title":". Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.","volume":"71","author":"Sivin","year":"2005","journal-title":"Contraception"},{"key":"R66-4-20210126","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2004.12.015","article-title":". Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.","volume":"72","author":"Fraser","year":"2005","journal-title":"Contraception"},{"key":"R67-4-20210126","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0010-7824(85)80005-6","article-title":". Fertility regulation in nursing women: VIII. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring.","volume":"32","author":"Diaz","year":"1985","journal-title":"Contraception"},{"key":"R68-4-20210126","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0039-128X(03)00140-5","article-title":". Nestorone: clinical applications for contraception and HRT.","volume":"68","author":"Sitruk-Ware","year":"2003","journal-title":"Steroids"},{"key":"R69-4-20210126","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.contraception.2007.08.006","article-title":". An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive.","volume":"76","author":"Fraser","year":"2007","journal-title":"Contraception"},{"key":"R70-4-20210126","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1210\/jcem.84.11.6162","article-title":". The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.","volume":"84","author":"Couzinet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R71-4-20210126","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-0528.1987.tb02322.x","article-title":". Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women.","volume":"94","author":"Bazin","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"R72-4-20210126","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/13625187.2011.614029","article-title":". Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 244 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 217 regimen.","volume":"16","author":"Mansour","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R73-4-20210126","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.contraception.2012.07.001","article-title":". Pharmacokinetic profile of nomegestrol acetate and 17beta-estradiol after multiple and single dosing in healthy women.","volume":"87","author":"Gerrits","year":"2013","journal-title":"Contraception"},{"key":"R74-4-20210126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":". Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen.","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R75-4-20210126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/humrep\/12.4.708","article-title":". Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant).","volume":"12","author":"Devoto","year":"1997","journal-title":"Hum Reprod"},{"key":"R76-4-20210126","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.contraception.2006.07.013","article-title":". Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year.","volume":"74","author":"Barbosa","year":"2006","journal-title":"Contraception"},{"key":"R77-4-20210126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0015-0282(97)81905-X","article-title":". Changes in the menstrual bleeding of users of a subdermal contraceptive implant of nomegestrol acetate (Uniplant) do not influence sexual frequency, sexual desire, or sexual enjoyment.","volume":"67","author":"Barnhart","year":"1997","journal-title":"Fertil Steril"},{"key":"R78-4-20210126","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0010-7824(93)90112-K","article-title":"One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant).","volume":"47","author":"Coutinho","year":"1993","journal-title":"Contraception"},{"key":"R79-4-20210126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0010-7824(95)00263-4","article-title":". Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant.","volume":"53","author":"Coutinho","year":"1996","journal-title":"Contraception"},{"key":"R80-4-20210126","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.steroids.2003.09.001","article-title":". Clinical experience with trimegestone as a new progestin in HRT.","volume":"68","author":"Grubb","year":"2003","journal-title":"Steroids"},{"key":"R81-4-20210126","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/MCB.18.3.1369","article-title":". The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.","volume":"18","author":"Wagner","year":"1998","journal-title":"Mol Cell Biol"},{"key":"R82-4-20210126","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril"},{"key":"R83-4-20210126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.mce.2012.02.021","article-title":"The immninent dawn of SPRMs in obstetrics and gynecology.","volume":"358","author":"Chabbert-Buffet","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R84-4-20210126","first-page":"933","article-title":". The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy.","volume":"294","author":"Herrmann","year":"1982","journal-title":"C R Seances Acad Sci III"},{"key":"R85-4-20210126","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM198612183152501","article-title":". Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone).","volume":"315","author":"Couzinet","year":"1986","journal-title":"N Engl J Med"},{"key":"R86-4-20210126","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.contraception.2009.12.012","article-title":"Mifepristone: where do we come from and where are we going Clinical development over a quarter of a century.","volume":"82","author":"Spitz","year":"2010","journal-title":"Contraception"},{"key":"R87-4-20210126","first-page":"243","article-title":". Low-dose mifepristone for uterine leiomyomata.","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R88-4-20210126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":". The spectrum of endometrial pathology induced by progesterone receptor modulators.","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"R89-4-20210126","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.humpath.2010.11.003","article-title":". Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone.","volume":"42","author":"Fiscella","year":"2011","journal-title":"Hum Pathol"},{"key":"R90-4-20210126","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/oxfordjournals.humrep.a137776","article-title":". Inhibition of ovulation by low-dose mifepristone (RU 486).","volume":"7","author":"Ledger","year":"1992","journal-title":"Hum Reprod"},{"key":"R91-4-20210126","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/oxfordjournals.humrep.a136283","article-title":". Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days.","volume":"10","author":"Baird","year":"1995","journal-title":"Hum Reprod"},{"key":"R92-4-20210126","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/humrep\/13.4.793","article-title":". Effects of long-term low-dose mifepristone on reproductive function in women.","volume":"13","author":"Croxatto","year":"1998","journal-title":"Hum Reprod"},{"key":"R93-4-20210126","first-page":"CD001324","article-title":". Interventions for emergency contraception.","volume":"2","author":"Cheng","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R94-4-20210126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jcem.87.1.8140","article-title":". Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.","volume":"87","author":"Brown","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R95-4-20210126","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":". A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).","volume":"22","author":"Lakha","year":"2007","journal-title":"Hum Reprod"},{"key":"R96-4-20210126","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2006.08.013","article-title":". Weekly contraception with mifepristone.","volume":"75","author":"Pei","year":"2007","journal-title":"Contraception"},{"key":"R97-4-20210126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0015-0282(98)00306-9","article-title":". Contraceptive efficacy of low doses of mifepristone.","volume":"70","author":"Marions","year":"1998","journal-title":"Fertil Steril"},{"key":"R98-4-20210126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0010-7824(97)00115-7","article-title":"Effect of once weekly administration of mifepristone on ovarian function in normal women.","volume":"56","author":"Chen","year":"1997","journal-title":"Contraception"},{"key":"R99-4-20210126","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/oxfordjournals.humrep.a136809","article-title":". The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.","volume":"3","author":"Swahn","year":"1988","journal-title":"Hum Reprod"},{"key":"R100-4-20210126","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.ajog.2008.09.005","article-title":". Evaluation of mifepristone as a once a month contraceptive pill.","volume":"200","author":"Agarwal","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R101-4-20210126","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/oxfordjournals.humrep.a138157","article-title":". Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.","volume":"8","author":"Gemzell-Danielsson","year":"1993","journal-title":"Hum Reprod"},{"key":"R102-4-20210126","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.fertnstert.2006.02.115","article-title":". Toward developing a once-a-month pill: a double-blind, randomized, controlled trial of the effect of three single doses of mifepristone given at midcycle on the pattern of menstrual bleeding.","volume":"86","author":"Narvekar","year":"2006","journal-title":"Fertil Steril"},{"key":"R103-4-20210126","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","article-title":". In vitro antiprogestationalantiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.","volume":"88","author":"Attardi","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R104-4-20210126","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.fertnstert.2008.12.057","article-title":". Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914.","volume":"93","author":"Stratton","year":"2010","journal-title":"Fertil Steril"},{"key":"R105-4-20210126","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/humrep\/15.5.1092","article-title":". A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women.","volume":"15","author":"Stratton","year":"2000","journal-title":"Hum Reprod"},{"key":"R106-4-20210126","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/humrep\/deq157","article-title":". Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture.","volume":"25","author":"Brache","year":"2010","journal-title":"Hum Reprod"},{"key":"R107-4-20210126","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Group VAS. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R108-4-20210126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.contraception.2012.05.012","article-title":"Results from pooled phase III studies of ulipristal acetate for emergency contraception.","volume":"86","author":"Moreau","year":"2012","journal-title":"Contraception"},{"key":"R109-4-20210126","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2013.05.010","article-title":". Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens.","volume":"88","author":"Brache","year":"2013","journal-title":"Contraception"},{"key":"R110-4-20210126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.contraception.2014.01.003","article-title":". Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women.","volume":"89","author":"Levy","year":"2014","journal-title":"Contraception"},{"key":"R111-4-20210126","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":". Ulipristal acetate versus leuprolide acetate for uterine fibroids.","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R112-4-20210126","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":". Long-term treatment of uterine fibroids with ulipristal acetate.","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"R113-4-20210126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.contraception.2011.10.003","article-title":". Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.","volume":"85","author":"Brache","year":"2012","journal-title":"Contraception"},{"key":"R114-4-20210126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.contraception.2005.06.071","article-title":". Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.","volume":"73","author":"Croxatto","year":"2006","journal-title":"Contraception"},{"key":"R115-4-20210126","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2012.08.038","article-title":"Vaginal ring delivery of selective progesterone receptor modulators for contraception.","volume":"87","author":"Jensen","year":"2013","journal-title":"Contraception"}],"container-title":["Clinical Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:18:47Z","timestamp":1620955127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201412000-00004"}},"subtitle":["Modern Delivery Systems and Novel Formulations"],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000072","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}